DK0784632T3 - Fremgangsmåde til udvinding af højren von Willebrand-faktor - Google Patents

Fremgangsmåde til udvinding af højren von Willebrand-faktor

Info

Publication number
DK0784632T3
DK0784632T3 DK95935890T DK95935890T DK0784632T3 DK 0784632 T3 DK0784632 T3 DK 0784632T3 DK 95935890 T DK95935890 T DK 95935890T DK 95935890 T DK95935890 T DK 95935890T DK 0784632 T3 DK0784632 T3 DK 0784632T3
Authority
DK
Denmark
Prior art keywords
von willebrand
willebrand factor
rvwf
free
extracting
Prior art date
Application number
DK95935890T
Other languages
English (en)
Inventor
Bernhard Fischer
Hans-Peter Schwarz
Manfred Reiter
Friedrich Dorner
Peter Turecek
Johann Eibl
Uwe Schlokat
Wolfgang Mundt
Renate Den-Bouwmeester
Artur Mitterer
Falco-Guenter Falkner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Application granted granted Critical
Publication of DK0784632T3 publication Critical patent/DK0784632T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK95935890T 1994-10-04 1995-10-02 Fremgangsmåde til udvinding af højren von Willebrand-faktor DK0784632T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4435485A DE4435485C1 (de) 1994-10-04 1994-10-04 Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
PCT/EP1995/003892 WO1996010584A1 (de) 1994-10-04 1995-10-02 Verfahren zur gewinnung von hochreinem von willebrand-faktor

Publications (1)

Publication Number Publication Date
DK0784632T3 true DK0784632T3 (da) 1999-08-30

Family

ID=6529944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935890T DK0784632T3 (da) 1994-10-04 1995-10-02 Fremgangsmåde til udvinding af højren von Willebrand-faktor

Country Status (11)

Country Link
US (4) US5854403A (da)
EP (1) EP0784632B1 (da)
JP (1) JP3701028B2 (da)
AT (1) ATE175424T1 (da)
AU (1) AU698334B2 (da)
CA (1) CA2201714C (da)
DE (2) DE4435485C1 (da)
DK (1) DK0784632T3 (da)
ES (1) ES2128090T3 (da)
GR (1) GR3029837T3 (da)
WO (1) WO1996010584A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880327A (en) * 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
JP4216478B2 (ja) 1998-09-21 2009-01-28 パーダム、ハワード・イー 感温性の材料を処理する方法および装置
WO2001022810A2 (en) * 1999-09-28 2001-04-05 Us Transgenics, Inc. Transgenic animals expressing von willebrand factor (vwf) and vwf-related polypeptides
US20040185042A1 (en) 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US7780831B2 (en) * 2003-07-07 2010-08-24 The University Of North Carolina At Chapel Hill Assays for detection of von willebrand factor (vWF) multimers and for degradation of vWF by agents such as ADAMTS13 and related methods
US7771660B2 (en) * 2004-05-04 2010-08-10 University Of North Carolina At Chapel Hill Electrophoretic interactive spectral methods and devices for the detection and/or characterization of biological particles
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2008512097A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション アプタマー医薬品化学
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
AU2008261261B2 (en) 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
AU2014202595A1 (en) * 2007-12-28 2014-06-05 Baxalta GmbH Recombinant VWF Formulations
WO2009086400A2 (en) 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
DK2865760T3 (da) 2008-06-24 2018-01-15 Csl Behring Gmbh Faktor VIII, Von Willebrand Faktor eller komplekser deraf med forlænget in vivo halveringstid
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
EP2748180B1 (en) * 2011-10-14 2018-08-15 Baxalta GmbH Protein purification by anion exchange chromatography
CN103889445A (zh) 2011-10-18 2014-06-25 德国杰特贝林生物制品有限公司 硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
US10246485B2 (en) 2013-11-08 2019-04-02 Csl Limited Method to concentrate von willebrand factor or complexes thereof
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
AU2017205776B2 (en) 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
PT3648787T (pt) 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
BR112020002234A2 (pt) 2017-08-23 2020-07-28 Csl Behring Gmbh método para a filtragem de virus do fator von willebrand
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
NL8500961A (nl) * 1985-04-01 1986-11-03 Stichting Vrienden Van De Stic Cdna-codering voor de humane von willebrand-factor, plasmiden met een dergelijke cdna-codering respektievelijk fragmenten ervan, alsmede micro-organismen, welke dergelijke plasmiden bevatten.
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
DE3904354A1 (de) * 1989-02-14 1990-08-16 Behringwerke Ag Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
ES2087156T3 (es) * 1989-06-15 1996-07-16 Rorer Int Overseas Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
US5312747A (en) * 1990-12-17 1994-05-17 Li Yu Teh Isolation, purification and utilization of sialidase-L in the synthesis of 2,7-anhydro-N-acetylneuraminic acid and for the selective cleavage of sialylα2-3 D-galactose linkage
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
IT1256622B (it) * 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
JP3133338B2 (ja) * 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Also Published As

Publication number Publication date
EP0784632A1 (de) 1997-07-23
US5877152A (en) 1999-03-02
GR3029837T3 (en) 1999-06-30
WO1996010584A1 (de) 1996-04-11
DE4435485C1 (de) 1996-03-21
CA2201714C (en) 2002-07-02
ATE175424T1 (de) 1999-01-15
JP3701028B2 (ja) 2005-09-28
US5880265A (en) 1999-03-09
CA2201714A1 (en) 1996-04-11
ES2128090T3 (es) 1999-05-01
US5854403A (en) 1998-12-29
JPH11509721A (ja) 1999-08-31
DE59504750D1 (de) 1999-02-18
EP0784632B1 (de) 1999-01-07
US6103693A (en) 2000-08-15
AU3803195A (en) 1996-04-26
AU698334B2 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
DE59504750D1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
Calvete et al. A procedure for the large-scale isolation of major bovine seminal plasma proteins
CA2099138A1 (en) Chondroitinase, Process for Preparing the Same, and Pharmaceutical Composition Comprising the Same
Linde et al. Evidence for several γ-carboxyglutamic acid-containing proteins in dentin
ATE196092T1 (de) Wachstumshormon-enthaltendeproteinformulierung
NO965012D0 (no) Farmasöytisk preparat som omfatter glukagon
CA2282841C (en) A method of purifying factor viii/vwf-complex by means of cation exchange chromatography
DK304682A (da) Vandholdigt topisk praeparat og fremgangsmaade til formindskelse af vandtab fra saadanne praeparater
HUP0202124A2 (hu) Eljárás gyógyszerészetileg aktív fehérjék tisztítására kationcserélő kromatográfiával
EP0469985A1 (en) Process for manufacturing von Willebrand factor having a very high purity
DK610888A (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
CA2480226A1 (en) Stable pharmaceutical composition containing factor viii
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
PH24961A (en) Monocional antibodies for human non-small cell lung carcinomas
DK0419878T3 (da) Nye aprotinin-varianter og genteknologisk fremgangsmåde til mikrobiel fremstilling af disse varianter i homogent processeret form
Baugh et al. Separation of human factor VIII activity from the von Willebrand's antigen and ristocetin platelet aggregating activity
GR3025929T3 (en) Ein isolation and purification of lung surfactant prot
KR960705580A (ko) 단백질 C 또는 활성화 단백질 C를 안정화시키는 방법 및 안정화된 조성물(Method of stabilizing protein C or activated protein C and stabilized composition)
KR860008270A (ko) α-인터페론의 제조 및 정제 방법
Mirkin et al. Catecholamine binding protein: binding of tritium to a specific protein fraction of human plasma following in vitro incubation with tritiated noradrenaline
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.
ES2009587A6 (es) Un metodo para purificar un polipeptido.
Ishaq et al. Purification and identification of antigenic polypeptides of Sm and RNP antigens of goat liver
Kagimoto et al. A new hemoglobin variant: HB yatsushiro α2Aβ260Val→ Leu